| Description | Irsenontrine (E2027) is a selective and orally active inhibitor of phosphodiesterase 9 (PDE9), primarily used for researching neurological diseases. |
| In vitro | Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 ( PDE 9 ) inhibitor[3]. |
| In vivo | Irsenontrine (0.3, 3.3 mg/kg; p.o.) exhibits a significant ameliorative effect on the percentage of exploration of the novel object at 3.3 mg/kg in Scopolamine-induced rats[1]. Irsenontrine (1 mg/kg; p.o.) and memantine hydrochloride (1 mg/kg; p.o.) combined treatment group exhibits a significantly higher percentage of exploration of the novel object than memantine hydrochloride (1 mg/kg) alone[1]. |
| Synonyms | E2027, Irsenontrine |
| molecular weight | 390.443 |
| Molecular formula | C22H22N4O3 |
| CAS | 1429509-82-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Miyamoto, et al. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine. WO2018221550 A1 2. Hershey LA, et al. Pharmacological Management of Dementia with Lewy Bodies. Drugs Aging. 2019;36(4):309-319. 3. Eisai to present latest research on Alzheimer’s disease / dementia pipeline at the 14th international conference on Alzheimer’s & Parkinson’s diseases |